CIK 0001620463 · Non-accelerated filer<br>Smaller reporting company
LeonaBio, Inc.
Sign in to watch- Ticker
- LONA
- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- FY end
- Dec 31
- Entity type
- operating
- EIN
- 453368487
- Phone
- (425) 620-8501
- Business address
- 18706 NORTH CREEK PARKWAY, SUITE 104, BOTHELL, WA, 98011
- Former names
- Athira Pharma, Inc., M3 Biotechnology, Inc.
- Open-market buys, last 90 days
- $9,919,161,281
- in 1 filing
- Open-market sales, last 90 days
- $0
- in 0 filings
Net +$9,919,161,281. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
Reading 85 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2024-05-20 | Gengos Andrew CFO and Chief Business Officer | Grant or award | +10,000 | $1.34 | $13K | 93,804 |
| 2024-05-20 | CHURCH KEVIN CHIEF SCIENTIFIC OFFICER | Grant or award | +4,953 | $1.34 | $7K | 85,209 |
| 2024-05-20 | Worthington Mark GENERAL COUNSEL | Grant or award | +10,000 | $1.34 | $13K | 44,452 |
| 2024-04-15 | San Martin Javier CHIEF MEDICAL OFFICER | Grant or award · Stock Option (Right to Buy) | +400,000 | 400,000 | ||
| 2024-02-15 | Litton Mark James CEO | Grant or award · Stock Option (Right to Buy) | +650,000 | 650,000 | ||
| 2024-02-14 | Worthington Mark GENERAL COUNSEL | Grant or award · Stock Option (Right to Buy) | +220,000 | 220,000 | ||
| 2024-02-14 | CHURCH KEVIN CHIEF SCIENTIFIC OFFICER | Grant or award · Stock Option (Right to Buy) | +220,000 | 220,000 | ||
| 2024-02-14 | Gengos Andrew CFO AND CHIEF BUSINESS OFFICER | Grant or award · Stock Option (Right to Buy) | +280,000 | 280,000 | ||
| 2024-02-14 | Lenington Rachel COO AND CDO | Grant or award · Stock Option (Right to Buy) | +300,000 | 300,000 | ||
| 2024-01-05 | Lenington Rachel COO AND CDO | Sale | −2,412 | $2.91 | $7K | 13,395 |
| 2024-01-05 | Litton Mark James CEO | Sale | −4,820 | $2.91 | $14K | 144,397 |
| 2024-01-05 | Worthington Mark GENERAL COUNSEL | Sale | −2,412 | $2.91 | $7K | 34,452 |
| 2024-01-05 | Gengos Andrew CFO AND CHIEF BUSINESS OFFICER | Sale | −1,208 | $2.91 | $4K | 83,804 |
| 2024-01-05 | CHURCH KEVIN CHIEF SCIENTIFIC OFFICER | Sale | −2,412 | $2.91 | $7K | 80,256 |
| 2024-01-05 | Litton Mark James Chief Executive Officer | Sale | −4,820 | $2.91 | $14K | 144,397 |
| 2024-01-04 | Lenington Rachel COO AND CDO | Grant or award | +10,000 | 15,807 | ||
| 2024-01-04 | Litton Mark James CEO | Grant or award | +20,000 | 149,217 | ||
| 2024-01-04 | Worthington Mark GENERAL COUNSEL | Grant or award | +10,000 | 36,864 | ||
| 2024-01-04 | Gengos Andrew CFO AND CHIEF BUSINESS OFFICER | Grant or award | +5,000 | 85,012 | ||
| 2024-01-04 | CHURCH KEVIN CHIEF SCIENTIFIC OFFICER | Grant or award | +10,000 | 82,668 |
Page 9 of 10 · 187 trades